<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051735</url>
  </required_header>
  <id_info>
    <org_study_id>180946</org_study_id>
    <nct_id>NCT05051735</nct_id>
  </id_info>
  <brief_title>PARASTOP - Paracetamol With Strong Opioids</brief_title>
  <acronym>PARASTOP</acronym>
  <official_title>PARASTOP - Paracetamol With Strong Opioids. A Randomized, Double-blind, Parallel-group Non-inferiority Phase III Withdrawal Trial of Paracetamol Versus Placebo in Conjunction With Opioids for Moderate to Severe Cancer-related Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sykehuset Telemark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current guidelines recommend all people with cancer-related pain should be prescribed&#xD;
      paracetamol, even those receiving high doses of strong pain killers (opioids) such as&#xD;
      morphine. Although this has been shown in studies to be beneficial in other conditions, for&#xD;
      instance dental work and after surgery, it has not been shown to further improve pain in&#xD;
      people with cancer-related pain. Taking tablets is burdensome to patients and the study aims&#xD;
      to determine whether the inconvenience of taking eight extra paracetamol tablets per day can&#xD;
      be justified.&#xD;
&#xD;
      The study plans to show whether or not pain control is changed (non-inferior) when stopping&#xD;
      paracetamol compared to continued use of paracetamol in people already taking strong pain&#xD;
      killers for cancer-related pain. Voluntary participants who are taking a combination of&#xD;
      paracetamol and a strong opioid are recruited to the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish whether placebo with strong opioids compared to paracetamol together with strong opioids provides non-inferior analgesia for cancer-related pain.</measure>
    <time_frame>7 days</time_frame>
    <description>Numeric Rating Scale 0-10: Average pain intensity past 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To establish whether placebo with strong opioids compared to paracetamol with strong opioids changes opioid related side effects.</measure>
    <time_frame>7 days</time_frame>
    <description>Opioid Side Effects Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To establish whether placebo with strong opioids compared to paracetamol with strong opioids changes global rating of improvement.</measure>
    <time_frame>7 days</time_frame>
    <description>Patient Global Impression of Change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To establish whether placebo with strong opioids compared to paracetamol with strong opioids changes opioid requirements.</measure>
    <time_frame>7 days</time_frame>
    <description>Opioid consumption</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Cancer Pain</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paracetamol P.O. 500 mg 2 tablets four times a day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo P.O. 2 tablets four times a day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Paracetamol 500 mg</description>
    <arm_group_label>Paracetamol</arm_group_label>
    <other_name>Acetaminophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be ≥ 18 years of age inclusive, at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          -  ≥50 kg (due to paracetamol dosage)&#xD;
&#xD;
          -  Participants who are under palliative care or oncology service review&#xD;
&#xD;
          -  Diagnosis of metastatic cancer&#xD;
&#xD;
          -  Clinician-predicted life expectancy &gt;2 months&#xD;
&#xD;
          -  Receiving daily regular strong opioids for cancer pain&#xD;
&#xD;
          -  Receiving stable scheduled opioid dose last 48 hours*&#xD;
&#xD;
          -  Receiving paracetamol 1 gram x three or four times a day for at least five days&#xD;
&#xD;
          -  Average pain intensity past 24 hours ≥ 2 and ≤ 7 (NRS 0-10)*&#xD;
&#xD;
          -  Able to take study drug/placebo as tablets&#xD;
&#xD;
          -  Able to comply with all study procedures&#xD;
&#xD;
          -  Capable of giving signed informed consent as described in Appendix 1 which includes&#xD;
             compliance with the requirements and restrictions listed in the informed consent form&#xD;
             (ICF) and in this protocol.&#xD;
&#xD;
               -  It is allowed to repeat procedure within the screening period without considering&#xD;
                  the participant being a rescreen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy or hypersensitivity to any of the active substances or excipients&#xD;
             in the study drug&#xD;
&#xD;
          -  Known severe liver or renal failure equivalent with CTCAE Grade 3 or 4* precluding&#xD;
             continuation of paracetamol. (*Common Terminology Criteria for Adverse Events (CTCAE)&#xD;
             Version 5.0)&#xD;
&#xD;
          -  Participants receiving subcutaneous, intravenous, intrathecal, or epidural opioid&#xD;
             therapy&#xD;
&#xD;
          -  Participants receiving systemic anticancer treatment during the intervention period if&#xD;
             they are anticipated to have increasing pain or other symptoms related to the&#xD;
             treatment&#xD;
&#xD;
          -  Co-enrolment in other drug trials. Participants will not be enrolled in any other&#xD;
             on-going interventional clinical trial. Study participants may be enrolled in&#xD;
             non-interventional research (e.g. questionnaire, tissue collection studies)&#xD;
&#xD;
          -  Previously enrolled in this study&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ørnulf Paulsen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Telemark Hospital Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise Torpen</last_name>
    <phone>+4790864581</phone>
    <email>linyto@ous-hf.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Augusto Caraceni</last_name>
    </contact>
    <investigator>
      <last_name>Augusto Caraceni</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandra Pigni</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olav Fredheim</last_name>
    </contact>
    <investigator>
      <last_name>Olav Fredheim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OsloUH</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lise Torpen</last_name>
    </contact>
    <investigator>
      <last_name>Katarina Rønning Hagen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Telemark Hospital Trust</name>
      <address>
        <city>Skien</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ørnulf Paulsen</last_name>
    </contact>
    <investigator>
      <last_name>Ørnulf Paulsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitetssykehuset Nord-Norge</name>
      <address>
        <city>Tromsø</city>
        <zip>9019</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigve Andersen</last_name>
    </contact>
    <investigator>
      <last_name>Sigve Andersen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7030</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erik Torbjørn Løhre</last_name>
    </contact>
    <investigator>
      <last_name>Erik Torbjørn Løhre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vestfold Hospital trust</name>
      <address>
        <city>Tønsberg</city>
        <zip>3103</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arve Nordbø</last_name>
    </contact>
    <investigator>
      <last_name>Arve Nordbø</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Møre og Romsdal</name>
      <address>
        <city>Ålesund</city>
        <zip>6026</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jo Åsmund Lund</last_name>
    </contact>
    <investigator>
      <last_name>Jo Åsmund Lund</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edinburgh Cancer Research</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Fallon</last_name>
    </contact>
    <investigator>
      <last_name>Marie Fallon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Norway</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 11, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Ørnulf Paulsen</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Cancer Pain</keyword>
  <keyword>Pain</keyword>
  <keyword>Analgesics</keyword>
  <keyword>Sensory System Agents</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

